



## The Genetic Links to anxiety and depression (GLAD) study: Online recruitment into the largest recontactable study of depression and anxiety

Davies, M., Kalsi, G., Armour, C., Jones, I., McIntosh, A., Smith, D., Walters, J., Bradley, J., Kingston, N., Ashford, S., Beange, I., Brailean, A., Cleare, A., Coleman, J., Curtis, C., Curzons, S., Davis, K., Dowey, L., Gault, V. A., ... Breen, G. (2019). The Genetic Links to anxiety and depression (GLAD) study: Online recruitment into the largest recontactable study of depression and anxiety. *Behaviour Research and Therapy*, 123(103503), [103503]. <https://doi.org/10.1016/j.brat.2019.103503>

[Link to publication record in Ulster University Research Portal](#)

**Published in:**  
Behaviour Research and Therapy

**Publication Status:**  
Published (in print/issue): 01/12/2019

**DOI:**  
[10.1016/j.brat.2019.103503](https://doi.org/10.1016/j.brat.2019.103503)

**Document Version**  
Author Accepted version

**General rights**  
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**  
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [pure-support@ulster.ac.uk](mailto:pure-support@ulster.ac.uk).

# Journal Pre-proof



The Genetic Links to anxiety and depression (GLAD) study: Online recruitment into the largest recontactable study of depression and anxiety

Molly R. Davies, Gursharan Kalsi, Chérie Armour, Ian R. Jones, Andrew M. McIntosh, Daniel J. Smith, James T.R. Walters, John R. Bradley, Nathalie Kingston, Sofie Ashford, Ioana Beange, Anamaria Brailean, Anthony J. Cleare, Jonathan R.I. Coleman, Charles J. Curtis, Susannah C.B. Curzons, Katrina A.S. Davis, Le Roy C. Dowey, Victor A. Gault, Kimberley A. Goldsmith, Megan Hammond Bennett, Yoriko Hirose, Matthew Hotopf, Christopher Hübel, Carola Kanz, Jennifer Leng, Donald M. Lyall, Bethany D. Mason, Monika McAtarsney-Kovacs, Dina Monssen, Alexei Moulton, Nigel Ovington, Elisavet Palaiologou, Carmine M. Pariante, Shivani Parikh, Alicia J. Peel, Ruth K. Price, Katharine A. Rimes, Henry C. Rogers, Jennifer Sambrook, Megan Skelton, Anna Spaul, Eddy L.A. Suarez, Bronte L. Sykes, Keith G. Thomas, Allan H. Young, Evangelos Vassos, David Veale, Katie M. White, Janet Wingrove, NIHR BioResource consortium, Thalia C. Eley, Gerome Breen

PII: S0005-7967(19)30189-5

DOI: <https://doi.org/10.1016/j.brat.2019.103503>

Reference: BRT 103503

To appear in: *Behaviour Research and Therapy*

Received Date: 1 February 2019

Revised Date: 4 September 2019

Accepted Date: 23 October 2019

Please cite this article as: Davies, M.R., Kalsi, G., Armour, Ché., Jones, I.R., McIntosh, A.M., Smith, D.J., Walters, J.T.R., Bradley, J.R., Kingston, N., Ashford, S., Beange, I., Brailean, A., Cleare, A.J., Coleman, J.R.I., Curtis, C.J., Curzons, S.C.B., Davis, K.A.S., Dowey, L.R.C., Gault, V.A., Goldsmith, K.A., Bennett, M.H., Hirose, Y., Hotopf, M., Hübel, C., Kanz, C., Leng, J., Lyall, D.M., Mason, B.D., McAtarsney-Kovacs, M., Monssen, D., Moulton, A., Ovington, N., Palaiologou, E., Pariante, C.M., Parikh, S., Peel, A.J., Price, R.K., Rimes, K.A., Rogers, H.C., Sambrook, J., Skelton, M., Spaul, A., Suarez, E.L.A., Sykes, B.L., Thomas, K.G., Young, A.H., Vassos, E., Veale, D., White, K.M., Wingrove, J., NIHR BioResource consortium, Eley, T.C., Breen, G., The Genetic Links to anxiety and depression (GLAD) study: Online recruitment into the largest recontactable study of depression and anxiety, *Behaviour Research and Therapy* (2019), doi: <https://doi.org/10.1016/j.brat.2019.103503>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Ltd.

# **The Genetic Links to Anxiety and Depression (GLAD) Study: online recruitment into the largest recontactable study of depression and anxiety**

Authors: Molly R. Davies<sup>a,b</sup>, Gursharan Kalsi<sup>a,b</sup>, Chérie Armour<sup>c</sup>, Ian R. Jones<sup>d</sup>, Andrew M. McIntosh<sup>e</sup>, Daniel J. Smith<sup>f</sup>, James T. R. Walters<sup>d</sup>, John R. Bradley<sup>g</sup>, Nathalie Kingston<sup>g,h</sup>, Sofie Ashford<sup>g,i</sup>, Ioana Beange<sup>e</sup>, Anamaria Brailean<sup>a</sup>, Anthony J. Cleare<sup>a,b,j</sup>, Jonathan R.I. Coleman<sup>a,b</sup>, Charles J. Curtis<sup>a,b</sup>, Susannah C.B. Curzons<sup>a,b</sup>, Katrina A.S. Davis<sup>a,b,j</sup>, Le Roy C. Dowey<sup>k,l</sup>, Victor A. Gault<sup>k</sup>, Kimberley A. Goldsmith<sup>a,b</sup>, Megan Hammond Bennett<sup>a,b</sup>, Yoriko Hirose<sup>e</sup>, Matthew Hotopf<sup>a,b,j</sup>, Christopher Hübel<sup>a,b,m</sup>, Carola Kanz<sup>g,h</sup>, Jennifer Leng<sup>a,b</sup>, Donald M. Lyall<sup>f</sup>, Bethany D. Mason<sup>a,b</sup>, Monika McAtarsney-Kovacs<sup>a,b</sup>, Dina Monssen<sup>a,b</sup>, Alexei Moulton<sup>g,h</sup>, Nigel Ovington<sup>g,h</sup>, Elisavet Palaiologou<sup>a,b</sup>, Carmine M. Pariante<sup>a,b,j</sup>, Shivani Parikh<sup>a,b</sup>, Alicia J. Peel<sup>a,b</sup>, Ruth K. Price<sup>k</sup>, Katharine A. Rimes<sup>a</sup>, Henry C. Rogers<sup>a,b</sup>, Jennifer Sambrook<sup>g,h</sup>, Megan Skelton<sup>a,b</sup>, Anna Spaul<sup>a,b</sup>, Eddy L.A. Suarez<sup>a,b</sup>, Bronte L. Sykes<sup>a,b</sup>, Keith G. Thomas<sup>k</sup>, Allan H. Young<sup>a,b,j</sup>, Evangelos Vassos<sup>a</sup>, David Veale<sup>a,b,j</sup>, Katie M. White<sup>a,b</sup>, Janet Wingrove<sup>j</sup>, NIHR BioResource consortium, Thalia C. Eley<sup>a,b \*</sup>, Gerome Breen<sup>a,b \*</sup>

\*Joint senior authors

<sup>a</sup>Institute of Psychiatry, Psychology and Neuroscience, King's College London, Denmark Hill, Camberwell, London, UK

<sup>b</sup>UK National Institute for Health Research (NIHR) Biomedical Research Centre, South London and Maudsley Hospital, London, UK

<sup>c</sup>School of Psychology, Queens University Belfast (QUB), Belfast, Northern Ireland, UK

<sup>d</sup>MRC Centre for Neuropsychiatric Genetics and Genomics, Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK

<sup>e</sup>Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

<sup>f</sup>Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

<sup>g</sup>NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK

<sup>h</sup>Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK

<sup>i</sup>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

<sup>j</sup>South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham, Kent, UK

<sup>k</sup>School of Biomedical Sciences, Ulster University, Coleraine Campus, Northern Ireland, UK

<sup>l</sup>GreenLight Pharmaceuticals Limited, Unit 2, Block E, Nutgrove Office Park, Dublin 14, Ireland

<sup>m</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

## **Corresponding Author**

Corresponding author: Dr Gerome Breen, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Denmark Hill, Camberwell, London, UK

Email: [gerome.breen@kcl.ac.uk](mailto:gerome.breen@kcl.ac.uk)

Tel: +44 020 7848 0409

## Abstract

**Background:** Anxiety and depression are common, debilitating and costly. These disorders are influenced by multiple risk factors, from genes to psychological vulnerabilities and environmental stressors, but research is hampered by a lack of sufficiently large comprehensive studies. We are recruiting 40,000 individuals with lifetime depression or anxiety and broad assessment of risks to facilitate future research.

**Methods:** The Genetic Links to Anxiety and Depression (GLAD) Study ([www.gladstudy.org.uk](http://www.gladstudy.org.uk)) recruits individuals with depression or anxiety into the NIHR Mental Health BioResource. Participants invited to join the study (via media campaigns) provide demographic, environmental and genetic data, and consent for medical record linkage and recontact.

**Results:** Online recruitment was effective; 42,531 participants consented and 27,776 completed the questionnaire by end of July 2019. Participants' questionnaire data identified very high rates of recurrent depression, severe anxiety, and comorbidity. Participants reported high rates of treatment receipt. The age profile of the sample is biased toward young adults, with higher recruitment of females and the more educated, especially at younger ages.

**Discussion:** This paper describes the study methodology and descriptive data for GLAD, which represents a large, recontactable resource that will enable future research into risks, outcomes, and treatment for anxiety and depression.

## Key Words

"Anxiety" "Depression" "Behavior genetics" "Psychiatric Genetics" "Data Sharing" "Life Events"

## Highlights

- Online recruitment of 40,000 individuals with lifetime depression or anxiety
- Detailed online phenotyping combined with genetic and clinical data
- The study sample is severe, highly comorbid, with chronic psychopathology
- The study protocol enables recall of participants for future research and trials

## Abbreviations

SNP (single nucleotide polymorphism), GLAD (Genetic Links to Anxiety and Depression), NIHR (National Institute for Health Research), Improving Access to Psychological Therapies (IAPT), South London and Maudsley (SLaM), NHS (National Health Service), Service User Research Enterprise (SURE), Feasibility and Acceptability Support Team for Researchers (FAST-R), public relations (PR), standard operating procedures (SOPs), Clinical Research Networks (CRN), general practitioner (GP), Clinical Commissioning Group (CCG), Major depressive disorder (MDD), Generalised anxiety disorder (GAD)

## Acknowledgements

We gratefully acknowledge the participation of all GLAD Study volunteers, and thank the National Institute for Health Research (NIHR) Mental Health BioResource staff for their help with volunteer recruitment. This study presents independent research funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Further information can be found at <http://brc.slam.nhs.uk/about/core-facilities/bioresource>.

The views expressed are those of the authors and not necessarily those of the NHS, NIHR, HSC R&D Division, Department of Health, Queens University Belfast, or King's College London.

**Declaration of Interests**

Prof Breen has received honoraria, research or conference grants and consulting fees from Eli Lilly, Illumina and Otsuka. Prof Eley and Dr Breen are part-funded by a program grant from the UK Medical Research Council (MR/M021475/1). Prof Cleare has in the last three years received honoraria, travel funding, or consultancy fees from Lundbeck, Livanova, Allergan and Janssen. Prof McIntosh has received research support from Eli Lilly, Janssen, and the Sackler Foundation, and has also received speaker fees from Illumina and Janssen. Prof Walters has received grant funding from Takeda for work unrelated to the GLAD Study.

**Funding**

This work was supported by the National Institute of Health Research (NIHR) BioResource, NIHR Biomedical Research Centre [IS-BRC-1215-20018], HSC R&D Division, Public Health Agency [COM/5516/18], MRC Mental Health Data Pathfinder Award (MC\_PC\_17217), and the National Centre for Mental Health funding through Health and Care Research Wales.

## Introduction

Anxiety and depression are the most common psychiatric disorders worldwide, with a lifetime prevalence of at least 30% (Kessler et al. 2005; Bandelow and Michaelis 2015). Both are highly comorbid with each other and with other psychiatric disorders (Mineka, Watson, and Clark 1998), and account for 10% of all years lived with disability (World Health Organisation 2017). The World Health Organisation now considers depression to be the number one disorder by burden of disease (World Health Organisation 2017). Many risk factors for depression and anxiety are shared, including psychological (e.g. cognitive biases (Naragon-Gainey 2010; Michl et al. 2013)), environmental (e.g. stressful life events (Michl et al. 2013)), and genetic influences (which are ~60-100% shared (Waszczuk et al. 2014; Purves et al. 2017)). These findings on aetiology have been accompanied by an increasing evidence base of effective treatments, especially psychological (talking) therapies (Deacon and Abramowitz 2004; Hofmann and Smits 2008; Dobson 1989). Nevertheless, despite advancements in psychological therapies as well as medication, clinicians are unable to predict which treatment will work for whom. This means that the choice of first and subsequent treatments currently progresses by trial and error at the cost of prolonged disability, reduced hope of success/engagement, and increased risk of adverse events (Perlis 2016; Rush et al. 2006).

Decades of work estimate twin study heritability of both anxiety and depression at ~30-40% (Sullivan, Neale, and Kendler 2000), rising to ~60-70% for the recurrent forms of these disorders across several years (K. S. Kendler et al. 1993). Recent UK Biobank analyses confirm that common genetic variants (single nucleotide polymorphisms, or “SNPs”) account for a smaller but still significant ~15-30% of variation (“SNP-heritability”) in lifetime anxiety (Purves et al. 2017). Depression has a SNP-heritability of ~12-14% and shows substantial genetic overlap with anxiety (Purves et al. 2017). Recent genome-wide association studies (GWAS) have identified 102 genetic variants for depression and closely related phenotypes (Howard et al. 2019) and 5 genetic variants for anxiety (Purves et al. 2017), indicating that we are now entering the era where it will be possible to finally discover new biology for both disorders. In addition, these genetic advances suggest that it may be time to include genetic risk factors in research aimed at developing new treatments or predicting which therapies will work best for each patient (Keers et al. 2016; Lewis and Vassos 2017; Gaspar et al. 2018; Breen et al. 2016).

Both GWAS and sequencing studies have shown that there are few, if any, individual genetic variants with a large effect size. Instead, the overall heritability is made of the effect of many (probably thousands) genetic variants that individually have small effects. This type of genetic architecture is now commonly referred to as being polygenic. As such, almost all disorders affecting >0.5% of the population that show moderate to high heritability are now referred to as polygenic disorders. The use of genome-wide methodology has also confirmed that psychiatric genetics has moved beyond its replication crisis, as its results have proven much more replicable than those of candidate gene studies (Border et al. 2019).

Despite the broad range of established risk factors (Craske et al. 2017; Fliege et al. 2009; Burcusa and Iacono 2007), it is unclear how different types of influences combine to increase risk and influence treatment response. In particular, clinical/psychological (e.g. comorbidities), demographic (e.g. age), environmental (e.g. life events), and genetic influences have been studied largely independently, despite their evident interplay (Kendler, Gardner, and Prescott 2002). As such, more multidisciplinary research is needed. However, efforts to better understand the aetiology of these disorders require large sample sizes and detailed information on symptom presentation. Many studies exist worldwide with either the scale of participants or the thorough phenotyping needed, but few have both. In response to this, the

Genetic Links to Anxiety and Depression (GLAD) Study was developed to recruit >40,000 individuals into the newly established National Institute for Health Research (NIHR) Mental Health BioResource. Our sample size was based on the available funding and our aim to be one of the largest single studies (as opposed to previous meta-analyses) of individuals with a lifetime experience of clinical depression and anxiety, providing sufficient power for discovery analyses and for recall studies.


The NIHR Mental Health BioResource is an integral part of the overall NIHR BioResource for Translational Research (<https://bioresource.nihr.ac.uk/>), which has previously recruited approximately 100,000 individuals. However, a large majority of these volunteers were either healthy controls or have a physical health condition with no reported mental health disorder. This gap led to the creation of the NIHR Mental Health BioResource. GLAD is its first project and has the specific goal of recruiting a large number of participants with anxiety and depression to facilitate future recall and secondary data analysis studies. Recall studies would involve recontacting participants to take part in further research, such as clinical trials aimed at developing better therapies and interventions for anxiety and depression. The GLAD Study will also directly explore both genetic and environmental risk factors for depression and anxiety disorders, including the potential of polygenic risk scores (Purcell et al. 2009) created from analyses of related phenotypes to predict response to treatment and prognosis. GLAD aims to facilitate studies which need to combine genetic, phenotypic, and environmental exposure data by creating a large, homogeneously phenotyped cohort of individuals with depression or anxiety with all these types of data.

## Methods

### Pre-Launch Preparation

A focused and intense social media campaign was utilised to inform the public about the GLAD Study. We hoped that individuals with anxiety and depression would be encouraged to join given the online methodology, allowing them to respond to the questionnaires in a convenient time and location. The timeline leading up to the media launch is outlined in Figure 1. Experts in the field, patients, and individuals with lived experience of depression or anxiety were consulted at each stage of study development. The study team also consulted regularly with collaborators from the Australian Genetics of Depression Study who provided guidance and advice based on their experience of successfully implementing a similar study design in Australia (Byrne et al. 2019).

**Figure 1.** Steps to prepare for launch of the GLAD Study





### *Website Development, Design, and User Testing*

The website was developed in collaboration with a local company (Mindwave Ventures) in various stages. During the early stages of development and the design phase, we conducted user testing on the website by contacting individuals with lived experience through various routes. The first user testers were patient volunteers within the Improving Access to Psychological Therapies (IAPT) service at South London and Maudsley (SLaM) National Health Service (NHS) Foundation Trust. The second group of volunteers were members of the King's College London Service User Research Enterprise (SURE) and the Feasibility and Acceptability Support Team for Researchers (FAST-R). Third were volunteer individuals with lived experience who were actively involved with the charity Mind. Finally, staff from the charities Mind, MQ Mental Health, and the Mental Health Foundation gave feedback. All individuals provided input on the website content and usability, appearance, and study information and all volunteers (but not charity staff) were compensated £10 for their time. All feedback was reviewed by the study team and the lead investigators and incorporated into the final version of the website.

### *GLAD Study Spokespeople*

A wide range of charities, professional bodies, companies, influencers (defined as individuals with a large number of followers on social media), and individuals with lived experience were identified based on previous advocacy, involvement, or openness of mental health and treatment. These individuals and organisations were approached by the public relations (PR) company (Four Health Communications), the study team, and/or the co-investigators to introduce the study and invite them to collaborate.

We received support from many UK charities including Mind, MQ, Mental Health Foundation, Anxiety UK, OCD Action, Bipolar UK, HERO, No Panic, the Charlie Waller Memorial Trust, BDD Foundation, Maternal OCD, Rethink Mental Illness, SANE, MHFA England, Universities UK, and UK Youth. We also received significant support from two UK professional bodies for psychologists and psychiatrists, the British Psychological Society and the Royal College of Psychiatrists. Finally, three organisations (Royal Mail, Priory Group, and Barnardo's) agreed to circulate study information internally to their employees, and Priory Group additionally shared study information on social media.

Many of the charities, professional bodies, and influencers provided a quote about the GLAD Study to be shared with news outlets and on social media. Other forms of support from charities or professional bodies included circulating study information in member newsletters or magazines, publishing study information on their websites, and sharing the study on social media (<http://wke.lt/w/s/Ymfhz>). Influencers helped to promote the study on their social media channels or blogs. Individuals with lived experience allowed the GLAD Study team to share their stories on social media and news outlets. Of utmost importance, these individuals were available for interviews with broadcast and newspaper agencies and gave a personal voice to the campaign. Spokespeople who became actively involved in the publicity and circulation of the GLAD Study in the media and/or online were vital to the success of the campaign.

### *Standard Operating Procedures and Templates*

We created a variety of standard operating procedures (SOPs) and response templates to prepare for the logistical and administrative aspects of study launch and management. These included SOPs for saliva sample kit preparation and posting, website management, data protection, and participant contact. We established guides and SOPs for both email and social media responses to participant questions, concerns, and expressions of distress. These guidelines were reviewed by clinicians and by the Mental Health Foundation to ensure responses were appropriate, straightforward, and clear.

#### *Social Media Content and Visuals*

Social media content and visuals were designed with the aid of the PR company (which had experience of working on NHS projects), an independent videographer, and an animation company. These included a range of infographics and short videos, each designed to be informative and provide basic details for the public about the aims of GLAD and how to join the project. The campaign was targeted to a younger demographic (age 16 - 30) to enable more prolonged collection of longitudinal data and reflect the young age of onset of depression and anxiety disorders (Bandelow and Michaelis 2015; Christie et al. 1988; Kessler et al. 2005).

The infographics (Figure 2) emphasised the simplicity and ease of taking part. The consent animation (<https://youtu.be.com/SAE0yVNvWaA>) outlined key elements of the consent process to provide a simple and clear way to learn about the study, consistent with guidance from the Health Research Authority regarding multimedia use as a patient-friendly method of delivering vital consent information (Health Research Authority 2017). The consent animation was also included with the website version of the information sheet. The second video was a short film (<https://youtu.be/wzgvS8gU2Ss>) which outlined the study sign-up steps in a real-life, relatable way. Finally, the animation (<https://youtu.be.com/HUI5eFXevvk>) was an engaging 'call to action' to join the community of volunteers participating in the GLAD Study.

**Figure 2.** GLAD Study infographic shared on Twitter



Example of the infographic shared on Twitter to promote the GLAD study and explain the key steps involved in signing up

We created a six-week social media schedule for planned posts across Facebook, Instagram, and Twitter platforms which included both organic and promoted content. Most of the posts were accompanied by a video, infographic, or other imagery developed by the study team.

#### *Outreach to News Outlets*

The PR company circulated the press release and study information to news and broadcast agencies across England, and later across the rest of the UK. Interested parties organised interviews with the study investigators and/or influencers, charity or professional body representatives, and individuals with lived experience. The press releases and broadcasts were embargoed until the launch date to prevent pre-emptive publicity and provide uniform, widespread coverage across different media.

#### Recruitment

##### *Media Campaign: Study launch*

The PR company helped us to organise a widespread national media campaign which included traditional media (TV, radio, newspaper) and social media (Twitter, Facebook, Instagram) outreach during the study launch. Examples from the campaign can be viewed at this link: <http://wke.lt/w/s/Ymfhz>. In the first 24 hours, 8,004 participants had registered to the website, demonstrating the effectiveness of this strategy. The prepared social media schedule helped to maintain our recruitment numbers over the six-week period. Between 300-1,500 participants signed up to the study daily, with numbers fluctuating based on campaign expenditure and social media support from influencers and organisations.

Five months after the initial launch, the GLAD Study opened in Northern Ireland, Scotland, and Wales, in collaboration with researchers at Ulster University<sup>1</sup>, the University of Edinburgh, and Cardiff University. The press offices of the respective universities organised media outreach to local and national news outlets, and the PR company assisted in targeted social media advertisements for the various countries.

### *Clinical Recruitment*

In the 10 months following the launch, many NHS organisations in England contacted us interested in supporting the GLAD Study. As of July 2019, these included 12 Clinical Research Networks (CRN), 7 family doctor/general practitioner (GP) practices, 96 Trusts, 1 Clinical Commissioning Group (CCG), and 2 GP Federations. Sites were classified in 2 different categories with varying levels of involvement: 1) advertising sites which displayed study posters and leaflets in clinics and waiting areas, and 2) recruiting sites which conducted mail-outs, approached patients in the clinic or over the phone, and assisted patients through the study sign-up process.

### Sign-up Process

The sign-up process for enrolment in GLAD is given in Figure 3. Personal information and phenotypic data are collected entirely online through the GLAD Study website ([www.gladstudy.org.uk](http://www.gladstudy.org.uk)). Participants register on the website with their name, email address, phone number, date of birth, sex, and gender. They are then able to read the information sheet and provide consent. As part of the consenting process participants agree to long-term storage of their sample, requests to complete follow-up questionnaires, anonymised data sharing, recontact for future research studies based on their phenotype/genotype information, and access to their full medical and health related records. Following consent, participants complete the sign-up questionnaire to assess their eligibility. Eligibility criteria are restricted to participants that meet DSM-5 criteria for MDD or any anxiety disorder, based on responses to screening measures in our online sign-up questionnaire. More information about the measures in the sign-up questionnaire are included below. Eligible participants are then sent an Isohelix saliva DNA sample kit. Saliva samples are sent via Freepost to the NIHR National Biosample Centre in Milton Keynes for processing and storage. Once participants have returned their saliva sample, they become full members of the GLAD Study (and of the NIHR BioResource) and are eligible to take part in future studies.

Email reminders are sent to participants who do not complete their sign-up steps. Up to four automated reminder emails are sent through the website up to six months post starting sign-up. Once online sign-up steps are completed, a maximum of four reminder emails are sent to participants regarding the saliva samples up to six months from the date the kit was sent. We conduct additional phone call or text message reminders to participants who have not returned their saliva kits within three months of signing-up.

Clinical data will be linked to genotype and phenotype data to provide additional information about participants' medical history, diagnoses, and treatments relevant to current and future research projects. Eligibility for collaborating studies can then be assessed utilising all phenotypic, genetic, and clinical data. Members may then be contacted up to four times per year to take part in future studies, either through the website or by the GLAD Study or NIHR BioResource teams, with access granted via established NIHR BioResource access protocols (see below for further detail). As part of the community of members, participants will also have access to useful information and links on the "Useful Links" page

---

<sup>1</sup> Professor Chérie Armour, the Principal Investigator (PI) in Northern Ireland (NI) moved institution during the course of the study from Ulster University to Queens University Belfast, remaining as the NI PI.

of the study website. Members will also be invited to take part in follow-up questionnaires to provide longitudinal data on their symptoms.

**Figure 3.** Stages of participant sign-up and involvement in the GLAD Study



## Measures

### *Sign-up Questionnaire*

The sign-up questionnaire was designed to assess core demographic and personal information as well as detailed psychological and behavioural phenotyping relevant to anxiety and depression (for full measure names see Table 1). We included lifetime measures of major depressive disorder (MDD), atypical depression, and generalised anxiety disorder (GAD, adapted from CIDI-SF (Patten et al. 2000) and ICD-11 checklists (Kogan et al. 2016), supplemented with items enabling lifetime assessment of DSM-5 specific phobia, social phobia, panic disorder and agoraphobia. These items were adapted from the Australian Genetics of Depression Study questionnaire (Byrne et al. 2019).

We also assessed current depressive symptoms (PHQ-9 (Kroenke, Spitzer, and Williams 2001)), and those with a score of five or above on the PHQ 9 (indicating a current episode of depression) were asked additional questions related to current treatment-resistant depression (MSM-SR (Fekadu, Donocik, and Cleare 2018)). Other measures of current psychopathology included possible mania/hypomania (MDQ (Hirschfeld 2002)), current general anxiety symptoms (GAD-7 (Spitzer et al. 2006)), post-traumatic stress disorder symptoms (PCL-6 (Lang et al. 2012)), alcohol use (AUDIT-C (Saunders et al. 1993)), psychotic symptoms (adapted CIDI (McGrath et al. 2015)), personality disorder symptoms (SAS-PD (Olajide et al. 2018)), and work and social adjustment (WSAS (Mundt et al. 2002)). Additional measures were included to assess subjective well-being (WHOQOL Group 1994), recent adverse life events, five childhood trauma items (Glaesmer et al. 2013) representing the five subscales of the full Childhood Trauma Questionnaire (Pennebaker and Susman 2013), domestic violence (Davis et al. 2018), and catastrophic trauma (Davis et al. 2018).

To facilitate future meta-analyses with other cohorts, measures were selected when possible to align with the UK Biobank Mental Health Questionnaire (MHQ) (Davis et al. 2018). Participants were also asked to report if they have taken part in the UK Biobank. Some aspects of the UK Biobank MHQ were not selected for the sign-up questionnaire in order to make space for additional measures more relevant here. Furthermore, detailed questions on self-harm and suicide were not asked during sign-up due to concerns from the study team and the SLaM Research and Development (R&D) department of insufficient clinical support in the case of reported adverse events, although the single suicidal ideation item in the PHQ-9 was retained as this measure is validated and widely used.

**Table 1.** GLAD Study sign-up questionnaire measures

Assessment/Topic	Purpose	Source
<b>Lifetime depression</b>	Lifetime assessment of major depressive disorder	Adapted Composite International Diagnostic Interview – Short Form (CIDI-SF)
<b>Lifetime atypical depression</b>	Lifetime assessment of atypical depression	Adapted DSM-5/ICD-11 checklists
<b>Lifetime anxiety</b>	Lifetime assessment of generalised anxiety disorder	Adapted Composite International Diagnostic Interview – Short Form (CIDI-SF)
<b>Lifetime specific phobia</b>	Lifetime assessment of specific phobia	Adapted DSM-5/ICD-11 checklists
<b>Lifetime social phobia</b>	Lifetime assessment of social phobia	Adapted DSM-5/ICD-11 checklists
<b>Lifetime panic disorder</b>	Lifetime assessment of panic disorder	Adapted DSM-5/ICD-11 checklists
<b>Lifetime agoraphobia</b>	Lifetime assessment of agoraphobia	Adapted DSM-5/ICD-11 checklists
<b>Current depressive symptoms</b>	Assess severity and presence/absence of current depression.	Patient Health Questionnaire 9-items (PHQ-9)
<b>Treatment-resistant depression</b>	Assess treatments during most recent or current depressive episode to screen for treatment-resistant	Maudsley Staging Model of Treatment Resistance, Modified Self-Report (MSM-SR)
<b>Possible mania/hypomania</b>	Screen participants for possible episodes of hypomania or mania	The Mood Disorder Questionnaire (MDQ)
<b>Current general anxiety symptoms</b>	Assess the severity and presence/absence of current anxiety	Generalised Anxiety Disorder 7-item scale (GAD-7)
<b>Current post-traumatic stress disorder symptoms</b>	Screen for presence and severity of PTSD symptoms.	Post-traumatic stress disorder checklist, civilian version 6-items (PCL-6)
<b>Alcohol use</b>	Screen for alcohol dependence in the past year	Alcohol Use Disorders Identification Test (AUDIT)
<b>Psychotic symptoms</b>	Assess lifetime psychotic experiences	Adapted CIDI
<b>Personality disorders</b>	Assess the severity of personality disorders.	Standardized Assessment of Severity of Personality Disorder 9-items (SASPD)
<b>Work and social adjustment</b>	Assess functional impairment due to psychopathology	Work and Social Adjustment Scale (WSAS)
<b>Subjective wellbeing</b>	Assesses subjective well-being, specifically positive emotion and meaning	Two hedonic ('positive emotion') questions and a eudaimonic ('meaning') question from WHO-Quality of Life (WHOQOL)
<b>Adversities in childhood</b>	Identify presence/absence of childhood abuse and neglect	Childhood Trauma Screener short version (CTS-5)
<b>Adult domestic abuse and catastrophic trauma</b>	Identify victims of adult domestic abuse.	A 5-item domestic abuse screen developed for the UK Biobank Mental Health Questionnaire, adapted from the national crime survey and CTS-5, and 5 items on



### *Optional Questionnaires*

Once participants completed the sign-up questionnaire, they were invited to take part in additional, optional questionnaires (SM 1). Optional questionnaires to assess a wider number of psychiatric phenotypes and symptoms included measures of fear (Fear Survey Schedule (Wolpe and Lang 1964)), drug use (DUDIT (Berman et al. 2003)), obsessive-compulsive disorder (OCI-R (Foa et al. 2002)), post-traumatic stress disorder (PCL-5 (Weathers et al. 2013)), trauma (Kopenen, personal communication), postnatal depression (EPDS (Cox, Holden, and Sagovsky 1987)), body dysmorphic disorder (DCQ (Mancuso, Knoesen, and Castle 2010)), eating disorders (Thornton et al. 2018; Herman et al. 2016; Allison, Stunkard, and Thier 2004; Hildebrandt, Langenbucher, and Schlundt 2004), and vomit phobia (SPOVI (Veale et al. 2013)).

Other optional projects relate to lifestyle and personal history, asking detailed questions on participants' experience of healthcare, life events (Weathers et al. 2013), work and sleep, general health and lifestyle, gambling, and headaches and migraines (Byrne et al. 2019). Optional questionnaires were made available to all participants, except those on vomit phobia and postnatal depression which were only offered to participants based on responses to screening questions in the sign-up questionnaire. Additional follow-up questionnaires will be sent to participants annually to provide longitudinal data on symptoms and outcomes.

### Genotyping

All GLAD samples will be genotyped as part of core NIHR BioResource funding. For genotyping we are using the UK Biobank v2 Axiom array, consisting of >850,000 genetic variants (Bycroft et al. 2018), designed to give optimal information about other correlated genetic variants. This careful design means that imputation of the data with large whole genome sequencing reference datasets will yield >10 million common genetic variants per individual. We use Affymetrix software and the UK Biobank pipeline software to assign genotypes and perform standard quality control measures in PLINK (Chang et al. 2015) or equivalent software packages and R (Team 2015). Analyses will be conducted in PLINK in the first instance.

### Ethical Approval

The GLAD Study was approved by the London - Fulham Research Ethics Committee on 21st August 2018 (REC reference: 18/LO/1218) following a full review by the committee. The NIHR BioResource has been approved as a Research Tissue Bank by the East of England - Cambridge Central Committee (REC reference: 17/EE/0025). Prior to submission for ethical approval, this research was reviewed by a team with experience of mental health problems and their carers who have been specially trained to advise on research proposals and documentation through the Feasibility and Acceptability Support Team for Researchers (FAST-R): a free, confidential service in England provided by the NIHR Maudsley Biomedical Research Centre via King's College London and South London and Maudsley NHS Foundation Trust.

### Analysis

### *Genetics and combined predictors of anxiety and depression*

The GLAD data can be used alongside UK Biobank for meta-analyses, with UK Biobank participants and/or other NIHR Bioresource participants as healthy controls, to maximise statistical power. One of our primary genomic aims is to utilise polygenic scores created from very large genome-wide analyses of related traits (e.g. anxiety) as potential predictors of depression, anxiety, and treatment response in our sample. There are a number of well-powered polygenic scores now available in the field not only for psychiatric traits but also intelligence and its proxies (Selzam et al. 2017) and other relevant predictors. We aim to combine these polygenic scores with significant clinical predictors to produce a combined clinical/genetic risk index.

We envision the GLAD sample to also be incorporated either in large genome-wide association studies, contributing to meta-analyses, or in clinical trials, for example researching genetic, epidemiological or social risk factors of anxiety and depression.

### Future Research and Collaborations

Researchers wishing to access GLAD Study participants or data are invited to submit a data and sample access request to the NIHR BioResource to request a collaboration, following the procedures outlined in the access request protocol (SM 2). Applications will be reviewed by the NIHR Steering Committee to assess the study aims and to check ethical approvals and protocols. Collaborations can range from sharing of anonymised data or samples to recontact of participants for additional studies, including experimental medicine studies and clinical trials. Eligibility for future research can be targeted to specific genotypes and/or phenotypes of interest.

## **Results**

### *Sample Descriptors*

Recruitment of the GLAD Study is ongoing. All results that follow are from participants recruited before 25 July 2019. As of this date, 42,531 participants had consented to the GLAD Study, with approximately 35% drop-off rate at each stage of the sign-up process. This resulted in 27,991 (65.8%) having completed the questionnaire, with 27,776 (99.2%) screened as eligible and sent a saliva kit. Of those participants which were sent a kit, 18,663 (67.2%) have returned a saliva sample thus far.

In the current sample, the mean age is 38.1 with most participants being female, white, and in paid employment or self-employed (Table 2). The GLAD sample is younger and more female (Figure 4) and has a higher proportion of individuals with a university degree (Figure 5) than the general UK population. For example, 13.1% of our sample is female aged 25-29 compared to only 4.2% of the UK population. This difference is seen across all age groups under 60. Similarly, in the age-range 25-34 years, 68.9% of the sample have a university degree, whereas in England and Wales this is only 40.4%. In total, 54.8% of the GLAD sample have a university degree compared to 27.2% of the English and Welsh population. Matching educational attainment data was not readily available for Northern Ireland and Scotland.

**Table 2.** Descriptors of GLAD sample, July 2019




	Percent*
Sex	
Male	20.3%
Female	79.7%
Gender	
Transgender	1.5%
Sexuality	
Heterosexual	73.4%
Homosexual	6.5%
Bisexual	15.5%
Asexual	1.3%
Self-define	3.1%
Ethnicity	
White	94.8%
Mixed	2.5%
Asian or Asian British	1.2%
Black or Black British	0.5%
Arab	0.1%
Other	0.9%
Education (highest level achieved)	
College or university degree	54.8%
A levels/AS levels or equivalent	22.7%
O levels/GCSEs or equivalent	14.8%
CSEs or equivalent	1.8%
Employment	
Employed	59.5%
Retired	5.7%
Unable to work because of sickness or disability	11.8%
Unemployed, looking after home/family, or doing voluntary work	8.9%
Full or part-time student	13.0%
Relationship status	
Single	27.8%
Relationship	32.2%
Married/civil partnership	30.3%
Divorced/separated	7.6%
Widowed	1.1%
Smoking status	
Current	17.5%
Former	31.9%
Never	50.6%
Handedness	
Right handed	87.2%
Left handed	11.1%
Ambidextrous	1.7%
Received treatment**	
Any treatment	96.1%

Psychological (talking) therapies	81.6%
Medication	89.7%

\*Where totals do not sum to 100%, the remaining % was due to incomplete data from those who declined to answer.


\*\*Treatment percentages were only calculated for participants who screened positively for MDD or GAD. Participants were asked to select all that applied in response to the question "Did you ever try or are currently trying the following for these problems?" Participants are considered to have received treatment if they indicated they tried medication prescribed for at least two weeks or tried psychotherapy or other talking therapy more than once.

**Figure 4.** Distribution of sex and age in the GLAD sample compared to the UK population



Comparison of age and sex characteristics between the GLAD sample and the general population of the UK as measured in the 2011 census (Office for National Statistics, National Records of Scotland, and Northern Ireland Statistics and Research Agency 2016). Proportions of males in each age group are displayed on the left side of the graph, with female proportions on the right. Percentages represent the proportion out of the respective sample as a whole (GLAD or UK). For example, 2.8% of the UK population is male aged 16-19, compared to 0.7% of the GLAD population. GLAD participants are represented in light (male) and dark (female) shades of blue, while the UK population is represented in light (male) and dark (female) shades of green.

**Figure 5.** Proportion of individuals with university degrees within age groups in the GLAD sample compared to the English and Welsh population



Comparison of education level by age group between the GLAD sample and the general population of England and Wales as measured in the 2011 census (Office for National Statistics, National Records of Scotland, and Northern Ireland Statistics and Research Agency 2016). Data for Northern Ireland and Scotland was not readily available. Proportions of individuals without university degrees within each age group are displayed on the left side of the graph, with proportions of individuals with university degrees on the right. Percentages represent the proportion within each age group with or without a university degree. For example, 14% of the English population between the ages of 16-24 have a university degree compared to 36% of the GLAD population. GLAD participants are represented in dark (no university degree) and light (university degree) shades of blue, while the English/Welsh population is represented in dark (no university degree) and light (university degree) shades of green.

A high proportion of GLAD participants report the occurrence of at least one form of trauma or abuse throughout their lives. Child abuse was most commonly reported, with emotional abuse by parents or family being endorsed by 42.1% of the sample (in comparison to the estimated 9% of adults in England and Wales who experienced emotional abuse as a child (Office for National Statistics 2016)). Other forms of life stress are also frequently endorsed with 62.8% of the sample reporting at least one traumatic experience in their lives. Of note, few participants reported periods of inability to pay rent, reflecting low rates of poverty in the sample.

**Table 3.** Proportion of the GLAD sample reporting previous child abuse/neglect, domestic abuse, or traumatic life events

	Proportion of sample
--	----------------------


<b>Child abuse/neglect<sup>a</sup></b>	
Any abuse or neglect	55.4%
Emotional abuse	42.1%
Physical abuse	20.2%
Sexual abuse	20.1%
Emotional neglect	14.8%
Physical neglect	4.2%
<b>Domestic abuse<sup>b</sup></b>	
Any abuse	30.6%
Emotional abuse	37.0%
Physical abuse	19.0%
Sexual abuse	22.6%
<b>Stressful life event</b>	
Any stressful/traumatic life event <sup>d</sup>	62.8%
Sexual assault <sup>c</sup>	44.7%
Attacked, mobbed, or robbed <sup>c</sup>	26.7%
Life-threatening accident <sup>c</sup>	13.3%
Witnessed sudden/violent death <sup>c</sup>	15.4%
Life-threatening illness <sup>c</sup>	8.8%
War zone <sup>c</sup>	2.1%
Inability to pay rent	1.6%

<sup>a</sup>Childhood abuse was assessed by the Childhood Trauma Survey (CTS) (Glaesmer et al. 2013) which includes 5 items on a Likert scale, each relating to the frequency of a distinct type of abuse (emotional, physical, sexual) or neglect (emotional, physical). Percentages reflect the proportion of the sample scoring above the defined cut-off point for clinical utility on each item out of the total. <sup>b</sup>Domestic abuse and inability to pay rent was assessed by a separate adult trauma scale without pre-defined cut-offs, therefore cut-off points were devised by the study team based on the CTS scoring. <sup>a,b</sup>Any abuse or stressful/traumatic life event was defined as individuals who scored above the cut-off on at least one item on the respective scale. <sup>c</sup>The remaining stressful life events were assessed by combining the sum total of participants indicating "Yes, in the past 12 months" or "Yes, but not in the past 12 months" for each item. <sup>d</sup>Any stressful/traumatic life event was defined as individuals who scored above the cut-off point for inability to pay rent or indicated they had experienced one of the stressful/traumatic life events either in the past 12 months or in their lifetime.

### Psychopathology

As shown in Figure 6, the majority of participants reached diagnostic criteria for major depressive disorder, followed by panic disorder and generalised anxiety disorder. The majority of participants with depression reported recurrent episodes across the lifespan. A figure demonstrating self-reported clinician-provided diagnoses of mental health disorders (as opposed to questionnaire-assessed) in the GLAD sample can be found in supplementary materials (SM 3). Of note, self-reported clinician-provided diagnoses of GAD (77.2%) are twice as high as cases assessed by the questionnaire. The sample also has high rates of comorbidity, with 67.0% of screened MDD cases also screening positively for at least one of the anxiety disorders (GAD, specific phobia, social phobia, panic disorder, or agoraphobia), and 95.1% of screened GAD cases also screening positively for MDD.

**Figure 6.** Lifetime prevalence of probable psychiatric disorders in the GLAD sample.



Percentages refer to the proportion of participants who meet cut-off criteria on lifetime measures for the specified disorder as defined by the DSM-5 (American Psychiatric Association 2013) out of the total. Possible mania was assessed by the Mood Disorder Questionnaire (MDQ) (Hirschfeld 2002).

Retrospective reports of age of onset indicate a young average onset for the lifetime measures of MDD, GAD, specific phobia, social phobia, panic disorder, and agoraphobia (Table 4). Average age of onset across the anxiety disorders was ~15. Age of onset for GAD was added to the questionnaire in May 2019, therefore the descriptives below are based on responses from a subset of participants recruited after that date.

**Table 4.** Age of onset in GLAD sample for major depressive disorder, specific phobias, social phobia, panic disorder, and agoraphobia

	Median	Mean	SD
Major depressive disorder	16	18.61	8.98
Generalised anxiety disorder	16	19.37	11.87
Specific phobia	10	11.32	8.40
Social phobia	12	13.79	8.64
Panic disorder	16	18.80	10.21
Agoraphobia	15	16.90	10.10

Measures of current symptoms of psychopathology included in the questionnaire demonstrate high rates of current clinical presentation of MDD and GAD, with high levels of functional impairment (Table 5).

**Table 5.** Current symptoms of psychopathology and impairment in the GLAD sample.

	Mean	Range	SD	Proportion Clinical Severity	
Major depressive disorder <sup>a</sup>	11.00	0 - 27	6.92	Clinical (total)	83.7%
				Mild (5 - 9)	24.7%
				Moderate (10 - 14)	23.7%
				Moderately severe (15 - 19)	18.7%
				Severe (20+)	16.7%
Generalised anxiety disorder <sup>b</sup>	9.43	0 - 21	6.02	Clinical (total)	75.5%
				Mild (5 - 9)	30.7%
				Moderate (10 - 14)	21.1%
				Severe (15+)	23.9%
Post-traumatic stress disorder <sup>c</sup>	15.87	0-30	6.29	Clinical (14+)	60.2%
Personality disorder <sup>d</sup>	8.30	0 - 25	3.65	Clinical (total)	55.0%
				Mild (8 - 9)	21.9%
				Moderate (10+)	33.1%
Alcohol use <sup>e</sup>	7.06	0 - 40	6.48	At-risk (total)	38.7%
				Increasing risk (8 - 15)	27.0%
				Higher risk (16 - 19)	5.4%
				Possible dependence (20+)	6.4%
Functional Impairment <sup>f</sup>	16.99	0-40	9.07	Clinical (total)	77.8%
				Significant impairment (10 - 20)	43.5%
				Severe impairment (21+)	34.4%


Percentages refer to the proportion of participants out of the total sample who meet cut-off criteria on current measures for the specified disorder: <sup>a</sup> Criteria met for major depressive disorder on PHQ-9 (Kroenke, Spitzer, and Williams 2001) <sup>b</sup> Criteria met for generalised anxiety disorder on GAD-7 (Spitzer et al. 2006) <sup>c</sup> Criteria met for PTSD on PCL-6 (Lang et al. 2012) in the past month <sup>d</sup> Criteria met for a personality disorder on SASPD (Olajide et al. 2018) <sup>e</sup> Criteria met for at-risk alcohol dependence on AUDIT (Saunders et al. 1993) in the past year <sup>f</sup> Criteria met for functional impairment on WSAS (Mundt et al. 2002)

### Media Campaign

In order to assess the success of the media campaign, participants were asked to report how they found out about the GLAD Study at the end of the sign-up questionnaire. Results of the campaign were assessed 3 months after the initial launch in England. Participants who completed the questionnaire reported that the three most common ways of hearing about the study were through Facebook, print newspaper, and Twitter (SM 4).

The effectiveness of each recruitment strategy varied by age (see Figure 7). Of participants aged 16-29, the majority learned about the study through social media (Facebook, Twitter, Instagram, search engine), with only 12% receiving study information through traditional media (TV, radio, print newspaper, online tabloid). Participants aged 30-49 also primarily learned about the study through social media, but 22% within that range learned about the study through traditional media. Social media was less effective in reaching individuals aged 50+, with traditional media being the primary means of recruitment above that age.

**Figure 7. Media campaign drivers to complete questionnaires, by age group**



Data is based on responses from 12,714 participants recruited in England between September - December 2019 to assess the success of the launch campaign. Participants were prompted to select all relevant responses to the question "How did you hear about the GLAD Study?" Social media refers to Facebook, Twitter, Instagram, bloggers, and search engines. Traditional media refers to radio, TV, newspaper, and online tabloids. All remaining responses are included in the Other category.

## Discussion

The GLAD Study represents a large and comprehensive study of anxiety and depression and a valuable resource for future research. By achieving our goal of recruiting 40,000 participants with a lifetime occurrence of one of these disorders into the NIHR Mental Health BioResource, the study will collect detailed, homogenous phenotype and genotype data, thereby increasing power for genetic analyses. Importantly, the recontactable nature of GLAD means that researchers will be able to conduct new studies integrating psychological and genetic data.

Why integrate genetic data? GLAD provides researchers with a way of investigating polygenic and environmental effects in studies with participants. As such, the study is not merely a way to increase GWAS sample size, but also a way to increase the potential utility of genomics within psychological studies of all kinds. Previous efforts in depression and anxiety genetics have been hampered by the unreliable methodology of candidate gene studies (Border et al. 2019). However, Border also concluded that modern and successful genome-wide studies of depression, rigorously testing millions of genetic variants in large samples (e.g. CONVERGE consortium 2015; Wray et al. 2018), provide reliable evidence. The implications that these highly complex, but highly replicable, polygenic effects have for the field need to be investigated (Hyman 2018). GLAD exists to enable recruitment of participants into studies not only on the basis of their self-reported information and/or clinical records, but also on the basis of the increasingly well powered method of polygenic risk scoring. This approach combines risk alleles across the genome into a single quantitative measure for any one individual (Belsky and Harden 2019). For instance, a clinical trial could be undertaken with selection of participants based on past medical history and/or polygenic scores for a relevant trait.

External researchers will be able to apply for access to anonymised data and will have the opportunity to recontact participants for additional data collection. This offers the prospect of a wide range of future recall studies, including clinical trials, observational studies, neuroimaging, and experimental medicine. Recruitment for recall studies could also be targeted to participants with phenotypes or genotypes of interest by utilising GLAD data to screen for specific eligibility criteria, thereby simplifying and expediting the recruitment process for future studies. Furthermore, measures were in part selected to match other cohorts and facilitate meta-analysis with samples such as the UK Biobank, Generation Scotland, and the Australian Genetics of Depression Study, although demographic differences between the samples would need to be taken into account (e.g. age differences between GLAD and UK Biobank participants). We propose that the GLAD data could be useful for stratifying cases into distinct phenotypes of depression and anxiety to reduce heterogeneity, a strategy which has been shown to increase the power of genetic analyses to detect significant effects (CONVERGE consortium 2015; Power et al. 2017; Verduijn et al. 2017).

Initial descriptive analyses reveal that the current GLAD sample does not reflect the demographics of the general population of the UK. The limited ethnic diversity within the sample is not representative, with 95% of participants being white compared to 87% of the population (Office for National Statistics, National Records of Scotland, and Northern Ireland Statistics and Research Agency 2016). Similarly, although common mental disorders are more than twice as common in young women compared to young men, and 1.5 times more common in women overall (NHS Digital 2016), the GLAD sample remains disproportionately female. Finally, roughly double the proportion of the study sample report having a university degree compared to the English and Welsh population.

The GLAD sample as a whole also shows severe psychopathology. Our lifetime questionnaire diagnostic algorithm indicated that the majority of the sample have recurrent depression, and 20.9% report possible mania/hypomania. Over half the sample screen positively for a lifetime anxiety disorder, with panic disorder being the most common. Participants also show substantial comorbidity, in particular for GAD cases reporting a concurrent diagnosis of MDD. Our results show significantly higher comorbidity rates for GAD cases compared to a previous epidemiological study whereby 62.4% of GAD cases had a lifetime occurrence of MDD (Judd et al. 1998). However, this is likely further indication of the sample's severity, reflecting previous reports of higher rates of comorbid anxiety in patients with recurrent lifetime depression (Moffitt et al. 2007; Boland, Keller, Gotlib, and Hammen 2002). In terms of current symptoms, GLAD participants report moderate symptoms of depression, mild to moderate symptoms of anxiety, and significant functional impairment, indicating poor work and social adjustment. Finally, it was interesting to note that 55.0% of participants screened positive for mild-moderate personality disorder.

Severity levels are also demonstrated by the 96.1% of GLAD participants who report receiving treatment for depression or anxiety, although the study is open to individuals regardless of treatment receipt. In Western countries, it is estimated that between one-thirds and one-half of patients with depression or anxiety disorders do not receive a diagnosis and/or treatment (Kessler et al. 2002), a group not represented in our sample. However, even in those patients receiving treatment, recent research suggests that only 20% get minimally adequate treatment (Thornicroft et al. 2017), meaning that follow-up research on treatment efficacy in the GLAD sample would be highly valuable.

An unanticipated benefit of the campaign was the interest it generated from UK NHS sites around the country. Over 100 NHS sites, including Trusts and GP practices, contacted the study team with interest in



supporting recruitment, and many had learned about the study from the media campaign. The study was also adopted onto the NIHR Clinical Research Network (CRN) Portfolio which provides support and funding for NHS organisations that are involved in research. The combined approach of both general and clinical recruitment reaches a wider demographic of participants than either strategy alone. Patients recruited through clinics can also be assisted in signing up by a local clinician or research team to provide support throughout the process if needed.

In addition to collecting a large amount of data, the GLAD study represents a template for future online studies. The media campaign proved highly effective in recruiting a large number of participants in a short amount of time and demonstrates the success of such a broad outreach approach. Caution must be taken when interpreting the success of the different media campaign strategies, given the prolonged use of social media promotions in comparison to traditional media outlets; nonetheless social media was the most effective strategy for recruiting individuals under 50. Recruiting younger participants not only reflects the young average age of onset of anxiety and depression, approximately 11 (Bandelow and Michaelis 2015) and 24 (Christie et al. 1988; Kessler et al. 2003) respectively, but also helps to facilitate long-term follow up and recontact.

#### Limitations

As previously mentioned, the current demographics of study participants who completed the questionnaire are not representative of the population of the UK. This suggests a selection bias comparable to what has been observed in similar studies such as the UK BioBank (Fry et al. 2017; Adams et al. 2019). Results from analyses of the current GLAD sample therefore may not be generalisable to the whole population. Smaller studies could overcome these biases by selectively over-sampling males and individuals at the lower end of educational attainment to be more representative of the population.

However, efforts are being taken to recruit a wider demographic of participants into the study. Specifically, we will develop a targeted social media campaign to reach young men and collaborate with young male influencers to appeal to that audience. We will additionally prepare a future media campaign that focuses on depression and anxiety separately, with wording specific to each disorder, to attempt to reduce the high comorbidity rates in the sample. Furthermore, we are collaborating with local branches of the charity Mind. These are typically placed within the community and provide a range of mental health support services. Branches will be displaying posters and leaflets on site, posting on social media, and answering questions or providing assistance to potential participants interested in signing up. Recruitment through NHS services and the availability of local research teams within those sites will also help reach the general population and recruit individuals with a wider range of educational attainment.

Of particular importance, we are working with Black, Asian, and minority ethnic charities and influencers to conduct additional user testing to understand the barriers to participating for non-white individuals and increase outreach to diverse communities. Previous genetic studies have involved primarily individuals of white European ancestry (Haga 2010), and findings from these studies may not apply to individuals of non-white descent. By actively recruiting a diverse sample, our objective is to additionally facilitate research on typically underrepresented groups.

Another challenge of the study design is the drop-out rates following recruitment. At each stage of the sign-up process, a substantial number of participants did not complete the next step despite multiple

reminders. Unfortunately, we are unable to assess the demographics of participants who do not complete the sign-up questionnaire, but it is possible that the drop-outs are non-random and represent a certain phenotype, such as individuals with more severe symptoms or lower health literacy.

### Conclusion

The GLAD study offers a recontactable resource of participants with a lifetime occurrence of depression and anxiety disorders to facilitate future health research. The online study design and media recruitment strategy were effective in recruiting a large number of individuals with these disorders into the NIHR Mental Health BioResource. Recruitment is ongoing with the goal of completing recruitment of 40,000 individuals, making this the largest single study of depression and anxiety. We hope that this paper will not only demonstrate the effectiveness of the study methodology but will also raise awareness of the availability of this cohort to researchers in the field and promote future collaboration.

### **References**

- Allison, Kelly C., Albert J. Stunkard, and Sara L. Thier. 2004. *Overcoming Night Eating Syndrome: A Step-by-Step Guide to Breaking the Cycle*. New Harbinger Publications.
- American Psychiatric Association. 2013. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5®)*. American Psychiatric Pub.
- Bandelow, Borwin, and Sophie Michaelis. 2015. "Epidemiology of Anxiety Disorders in the 21st Century." *Dialogues in Clinical Neuroscience* 17 (3): 327–35.
- Berman, A., H. Bergman, T. Palmstierna, and F. Schlyter. 2003. "The Drug Use Disorders Identification Test (DUDIT) Manual." *Stockholm, Sweden: Karolinska Institutet*.
- Boland, R. J., Keller, M. B., Gotlib, I. H., & Hammen, C. L. 2002. "Course and Outcome of Depression." In *Handbook of Depression 2*, edited by Robert J. Boland and Martin B. Keller, 23–43. The Guilford Press.
- Border, Richard, Emma C. Johnson, Luke M. Evans, Andrew Smolen, Noah Berley, Patrick F. Sullivan, and Matthew C. Keller. 2019. "No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples." *The American Journal of Psychiatry* 176 (5): 376–87.
- Breen, G., Q. Li, B. L. Roth, P. O'Donnell, M. Didriksen, R. Dolmetsch, P. F. O'Reilly, et al. 2016. "Translating Genome-Wide Association Findings into New Therapeutics for Psychiatry." *Nature Neuroscience* 19 (11): 1392–96.
- Burcusa, Stephanie L., and William G. Iacono. 2007. "Risk for Recurrence in Depression." *Clinical Psychology Review* 27 (8): 959–85.
- Bycroft, Clare, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T. Elliott, Kevin Sharp, Allan Motyer, et al. 2018. "The UK Biobank Resource with Deep Phenotyping and Genomic Data." *Nature* 562 (7726): 203–9.
- Byrne, Enda M., Katherine M. Kirk, Sarah E. Medland, John J. McGrath, Richard Parker, Simone Cross, Lenore Sullivan, et al. 2019. "The Australian Genetics of Depression Study: Study Description and Sample Characteristics." *bioRxiv*. <https://doi.org/10.1101/626762>.
- Chang, Christopher C., Carson C. Chow, Laurent Cam Tellier, Shashaank Vattikuti, Shaun M. Purcell, and James J. Lee. 2015. "Second-Generation PLINK: Rising to the Challenge of Larger and Richer Datasets." *GigaScience* 4 (February): 7.
- Christie, K. A., J. D. Burke Jr, D. A. Regier, D. S. Rae, J. H. Boyd, and B. Z. Locke. 1988. "Epidemiologic Evidence for Early Onset of Mental Disorders and Higher Risk of Drug Abuse in Young Adults." *The American Journal of Psychiatry* 145 (8): 971–75.
- CONVERGE consortium. 2015. "Sparse Whole-Genome Sequencing Identifies Two Loci for Major Depressive Disorder." *Nature* 523 (7562): 588–91.
- Cox, J. L., J. M. Holden, and R. Sagovsky. 1987. "Detection of Postnatal Depression. Development of the 10-Item Edinburgh Postnatal Depression Scale." *The British Journal of Psychiatry: The Journal of Mental Science* 150 (June): 782–86.
- Craske, Michelle G., Murray B. Stein, Thalia C. Eley, Mohammed R. Milad, Andrew Holmes, Ronald M. Rapee, and Hans-Ulrich Wittchen. 2017. "Anxiety Disorders." *Nature Reviews. Disease Primers* 3 (May): 17024.
- Davis, Katrina A. S., Jonathan R. I. Coleman, Mark Adams, Naomi Allen, Gerome Breen, Breda Cullen, Chris Dickens, et al. 2018. "Mental Health in UK Biobank: Development, Implementation and Results from an Online Questionnaire Completed by 157 366 Participants." *BJPsych Open* 4 (3): 83–90.
- Deacon, Brett J., and Jonathan S. Abramowitz. 2004. "Cognitive and Behavioral Treatments for Anxiety Disorders: A Review of Meta-Analytic Findings." *Journal of Clinical Psychology* 60 (4): 429–41.
- Dobson, K. S. 1989. "A Meta-Analysis of the Efficacy of Cognitive Therapy for Depression." *Journal of Consulting and Clinical Psychology* 57 (3): 414–19.

- Fekadu, Abebaw, Jacek G. Donocik, and Anthony J. Cleare. 2018. "Standardisation Framework for the Maudsley Staging Method for Treatment Resistance in Depression." *BMC Psychiatry* 18 (1): 100.
- Fliege, Herbert, Jeong-Ran Lee, Anne Grimm, and Burghard F. Klapp. 2009. "Risk Factors and Correlates of Deliberate Self-Harm Behavior: A Systematic Review." *Journal of Psychosomatic Research* 66 (6): 477–93.
- Foa, Edna B., Jonathan D. Huppert, Susanne Leiberger, Robert Langner, Rafael Kichic, Greg Hajcak, and Paul M. Salkovskis. 2002. "The Obsessive-Compulsive Inventory: Development and Validation of a Short Version." *Psychological Assessment* 14 (4): 485–96.
- Gaspar, Hélène A., Zachary Gerring, Christopher Hübel, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Christel M. Middeldorp, Eske M. Derks, and Gerome Breen. 2018. "Using Genetic Drug-Target Networks to Develop New Drug Hypotheses for Major Depressive Disorder." *bioRxiv*. <https://doi.org/10.1101/304113>.
- Glaesmer, Heide, Andrea Schulz, Winfried Häuser, Harald J. Freyberger, Elmar Brähler, and Hans-Jürgen Grabe. 2013. "Der Childhood Trauma Screener (CTS) – Entwicklung und Validierung von Schwellenwerten zur Klassifikation." *Psychiatrische Praxis* 40 (04): e1–e1.
- Haga, Susanne B. 2010. "Impact of Limited Population Diversity of Genome-Wide Association Studies." *Genetics in Medicine: Official Journal of the American College of Medical Genetics* 12 (2): 81–84.
- Health Research Authority. 2017. "Applying a Proportionate Approach to the Process of Seeking Consent." 1.01. Policy and Public Affairs Directorate.
- Herman, Barry K., Linda S. Deal, Dana B. DiBenedetti, Lauren Nelson, Sheri E. Fehnel, and T. Michelle Brown. 2016. "Development of the 7-Item Binge-Eating Disorder Screener (BEDS-7)." *The Primary Care Companion to CNS Disorders* 18 (2). <https://doi.org/10.4088/PCC.15m01896>.
- Hildebrandt, Tom, Jim Langenbucher, and David G. Schlundt. 2004. "Muscularity Concerns among Men: Development of Attitudinal and Perceptual Measures." *Body Image* 1 (2): 169–81.
- Hirschfeld, Robert M. A. 2002. "The Mood Disorder Questionnaire: A Simple, Patient-Rated Screening Instrument for Bipolar Disorder." *Primary Care Companion to the Journal of Clinical Psychiatry* 4 (1): 9–11.
- Hofmann, Stefan G., and Jasper A. J. Smits. 2008. "Cognitive-Behavioral Therapy for Adult Anxiety Disorders: A Meta-Analysis of Randomized Placebo-Controlled Trials." *The Journal of Clinical Psychiatry* 69 (4): 621–32.
- Howard, David M., Mark J. Adams, Toni-Kim Clarke, Jonathan D. Hafferty, Jude Gibson, Masoud Shirali, Jonathan R. I. Coleman, et al. 2019. "Genome-Wide Meta-Analysis of Depression Identifies 102 Independent Variants and Highlights the Importance of the Prefrontal Brain Regions." *Nature Neuroscience* 22 (3): 343–52.
- Judd, L. L., R. C. Kessler, M. P. Paulus, P. V. Zeller, H. U. Wittchen, and J. L. Kunovac. 1998. "Comorbidity as a Fundamental Feature of Generalized Anxiety Disorders: Results from the National Comorbidity Study (NCS)." *Acta Psychiatrica Scandinavica. Supplementum* 393: 6–11.
- Keers, R., J. R. I. Coleman, K. J. Lester, S. Roberts, G. Breen, M. Thastum, S. Bögers, et al. 2016. "A Genome-Wide Test of the Differential Susceptibility Hypothesis Reveals a Genetic Predictor of Differential Response to Psychological Treatments for Child Anxiety Disorders." *Psychotherapy and Psychosomatics* 85 (3): 146–58.
- Kendler, Kenneth S., Charles O. Gardner, and Carol A. Prescott. 2002. "Toward a Comprehensive Developmental Model for Major Depression in Women." *The American Journal of Psychiatry* 159 (7): 1133–45.
- Kendler, K. S., M. C. Neale, R. C. Kessler, A. C. Heath, and L. J. Eaves. 1993. "The Lifetime History of Major Depression in Women. Reliability of Diagnosis and Heritability." *Archives of General Psychiatry* 50 (11): 863–70.
- Kessler, David, Olive Bennewith, Glyn Lewis, and Deborah Sharp. 2002. "Detection of Depression and

- Anxiety in Primary Care: Follow up Study." *BMJ* 325 (7371): 1016–17.
- Kessler, Ronald C., Patricia Berglund, Olga Demler, Robert Jin, Doreen Koretz, Kathleen R. Merikangas, A. John Rush, Ellen E. Walters, Philip S. Wang, and National Comorbidity Survey Replication. 2003. "The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R)." *JAMA: The Journal of the American Medical Association* 289 (23): 3095–3105.
- Kessler, Ronald C., Patricia Berglund, Olga Demler, Robert Jin, Kathleen R. Merikangas, and Ellen E. Walters. 2005. "Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication." *Archives of General Psychiatry* 62 (6): 593–602.
- Kogan, Cary S., Dan J. Stein, Mario Maj, Michael B. First, Paul M. G. Emmelkamp, and Geoffrey M. Reed. 2016. "The Classification of Anxiety and Fear-Related Disorders in the ICD-11." *Depression and Anxiety* 33 (12): 1141–54.
- Kroenke, K., R. L. Spitzer, and J. B. Williams. 2001. "The PHQ-9: Validity of a Brief Depression Severity Measure." *Journal of General Internal Medicine* 16 (9): 606–13.
- Lang, Ariel J., Kendall Wilkins, Peter P. Roy-Byrne, Daniela Golinelli, Denise Chavira, Cathy Sherbourne, Raphael D. Rose, et al. 2012. "Abbreviated PTSD Checklist (PCL) as a Guide to Clinical Response." *General Hospital Psychiatry* 34 (4): 332–38.
- Lewis, Cathryn M., and Evangelos Vassos. 2017. "Prospects for Using Risk Scores in Polygenic Medicine." *Genome Medicine* 9 (1): 96.
- Mancuso, Serafino G., Natalie P. Knoesen, and David J. Castle. 2010. "The Dysmorphic Concern Questionnaire: A Screening Measure for Body Dysmorphic Disorder." *The Australian and New Zealand Journal of Psychiatry* 44 (6): 535–42.
- McGrath, John J., Sukanta Saha, Ali Al-Hamzawi, Jordi Alonso, Evelyn J. Bromet, Ronny Bruffaerts, José Miguel Caldas-de-Almeida, et al. 2015. "Psychotic Experiences in the General Population: A Cross-National Analysis Based on 31,261 Respondents From 18 Countries." *JAMA Psychiatry* 72 (7): 697–705.
- Michl, Louisa C., Katie A. McLaughlin, Kathrine Shepherd, and Susan Nolen-Hoeksema. 2013. "Rumination as a Mechanism Linking Stressful Life Events to Symptoms of Depression and Anxiety: Longitudinal Evidence in Early Adolescents and Adults." *Journal of Abnormal Psychology* 122 (2): 339–52.
- Mineka, S., D. Watson, and L. A. Clark. 1998. "Comorbidity of Anxiety and Unipolar Mood Disorders." *Annual Review of Psychology* 49: 377–412.
- Moffitt, Terrie E., Honalee Harrington, Avshalom Caspi, Julia Kim-Cohen, David Goldberg, Alice M. Gregory, and Richie Poulton. 2007. "Depression and Generalized Anxiety Disorder: Cumulative and Sequential Comorbidity in a Birth Cohort Followed Prospectively to Age 32 Years." *Archives of General Psychiatry* 64 (6): 651–60.
- Mundt, James C., Isaac M. Marks, M. Katherine Shear, and John H. Greist. 2002. "The Work and Social Adjustment Scale: A Simple Measure of Impairment in Functioning." *The British Journal of Psychiatry: The Journal of Mental Science* 180 (May): 461–64.
- Naragon-Gainey, Kristin. 2010. "Meta-Analysis of the Relations of Anxiety Sensitivity to the Depressive and Anxiety Disorders." *Psychological Bulletin* 136 (1): 128–50.
- NHS Digital. 2016. "Survey Shows One in Three Adults with Common Mental Disorders Report Using Treatment Services - NHS Digital." NHS Digital. September 29, 2016. <https://digital.nhs.uk/news-and-events/news-archive/2016-news-archive/survey-shows-one-in-three-adults-with-common-mental-disorders-report-using-treatment-services>.
- Office for National Statistics. 2016. "Abuse during Childhood: Findings from the Crime Survey for England and Wales, Year Ending March 2016." Office for National Statistics. August 4, 2016. <https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/abuseduringchildhood/findingsfromtheyearendingmarch2016crimesurveyforenglandandwales>.

- Office for National Statistics, National Records of Scotland, and Northern Ireland Statistics and Research Agency. 2016. "2011 Census Aggregate Data. UK Data Service (Edition: June 2016)." <https://doi.org/10.5257/census/aggregate-2011-1>.
- Olajide, Kike, Jasna Munjiza, Paul Moran, Lesley O'Connell, Giles Newton-Howes, Paul Bassett, Gbolagade Akintomide, et al. 2018. "Development and Psychometric Properties of the Standardized Assessment of Severity of Personality Disorder (SASPD)." *Journal of Personality Disorders* 32 (1): 44–56.
- Patten, S. B., J. Brandon-Christie, J. Devji, and B. Sedmak. 2000. "Performance of the Composite International Diagnostic Interview Short Form for Major Depression in a Community Sample." *Chronic Diseases in Canada* 21 (2): 68–72.
- Pennebaker, J.W. & Susman, J.R. 2013. "Childhood Trauma Questionnaire." *Measurement Instrument Base for the Social Science*. <http://www.midss.org/sites/default/files/trauma.pdf>.
- Perlis, Roy H. 2016. "Abandoning Personalization to Get to Precision in the Pharmacotherapy of Depression." *World Psychiatry: Official Journal of the World Psychiatric Association* 15 (3): 228–35.
- Power, Robert A., Katherine E. Tansey, Henriette Nørmølle Buttenschøn, Sarah Cohen-Woods, Tim Bigdeli, Lynsey S. Hall, Zoltán Kutalik, et al. 2017. "Genome-Wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium." *Biological Psychiatry* 81 (4): 325–35.
- Purcell, Shaun M., Naomi R. Wray, Jennifer L. Stone, Peter M. Visscher, Michael C. O'Donovan, Patrick F. Sullivan, and Pamela Sklar. 2009. "Common Polygenic Variation Contributes to Risk of Schizophrenia and Bipolar Disorder." *Nature* 460 (7256): 748–52.
- Purves, Kirstin Lee, Jonathan R. I. Coleman, Christopher Rayner, John M. Hettema, Jürgen Deckert, Andrew M. McIntosh, Kristin K. Nicodemus, Gerome Breen, and Thalia C. Eley. 2017. "The Common Genetic Architecture of Anxiety Disorders." *bioRxiv*. <https://doi.org/10.1101/203844>.
- Rush, A. John, Madhukar H. Trivedi, Stephen R. Wisniewski, Andrew A. Nierenberg, Jonathan W. Stewart, Diane Warden, George Niederehe, et al. 2006. "Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR\*D Report." *The American Journal of Psychiatry* 163 (11): 1905–17.
- Saunders, John B., Olaf G. Aasland, Thomas F. Babor, Juan R. de La Fuente, and Marcus Grant. 1993. "Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II." *Addiction* 88 (6): 791–804.
- Selzam, S., E. Krapohl, S. von Stumm, P. F. O'Reilly, K. Rimfeld, Y. Kovas, P. S. Dale, J. J. Lee, and R. Plomin. 2017. "Predicting Educational Achievement from DNA." *Molecular Psychiatry* 22 (2): 267–72.
- Spitzer, Robert L., Kurt Kroenke, Janet B. W. Williams, and Bernd Löwe. 2006. "A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7." *Archives of Internal Medicine* 166 (10): 1092–97.
- Sullivan, P. F., M. C. Neale, and K. S. Kendler. 2000. "Genetic Epidemiology of Major Depression: Review and Meta Analysis." *The American Journal of Psychiatry* 157: 1552–62.
- Team, R. Core. 2015. "R: A Language and Environment for Statistical Computing." <http://143.107.212.50/web/packages/dplR/vignettes/timeseries-dplR.pdf>.
- Thornicroft, Graham, Somnath Chatterji, Sara Evans-Lacko, Michael Gruber, Nancy Sampson, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, et al. 2017. "Undertreatment of People with Major Depressive Disorder in 21 Countries." *The British Journal of Psychiatry: The Journal of Mental Science* 210 (2): 119–24.
- Thornton, Laura M., Melissa A. Munn-Chernoff, Jessica H. Baker, Anders Juréus, Richard Parker, Anjali K. Henders, Janne T. Larsen, et al. 2018. "The Anorexia Nervosa Genetics Initiative (ANGI): Overview and Methods." *Contemporary Clinical Trials* 74 (November): 61–69.



- Veale, David, Nell Ellison, Mark J. Boschen, Ana Costa, Chantelle Whelan, Francesca Muccio, and Kareina Henry. 2013. "Development of an Inventory to Measure Specific Phobia of Vomiting (Emetophobia)." *Cognitive Therapy and Research* 37 (3): 595–604.
- Verduijn, Judith, Yuri Milaneschi, Wouter J. Peyrot, Jouke Jan Hottenga, Abdel Abdellaoui, Eco J. C. de Geus, Johannes H. Smit, et al. 2017. "Using Clinical Characteristics to Identify Which Patients With Major Depressive Disorder Have a Higher Genetic Load for Three Psychiatric Disorders." *Biological Psychiatry* 81 (4): 316–24.
- Waszczuk, Monika A., Helena M. S. Zavos, Alice M. Gregory, and Thalia C. Eley. 2014. "The Phenotypic and Genetic Structure of Depression and Anxiety Disorder Symptoms in Childhood, Adolescence, and Young Adulthood." *JAMA Psychiatry* 71 (8): 905–16.
- Weathers, Frank W., Brett T. Litz, Terence M. Keane, Patrick A. Palmieri, Brian P. Marx, and Paula P. Schnurr. 2013. "The PTSD Checklist for DSM-5 (PCL-5)." National Center for PTSD. [www.ptsd.va.gov](http://www.ptsd.va.gov).
- Weathers, F. W., D. D. Blake, P. P. Schnurr, D. G. Kaloupek, B. P. Marx, and T. M. Keane. 2013. "The Life Events Checklist for DSM-5 (LEC-5) - Standard." National Center for PTSD. [https://www.ptsd.va.gov/professional/assessment/documents/LEC-5\\_Standard\\_Self-report.pdf](https://www.ptsd.va.gov/professional/assessment/documents/LEC-5_Standard_Self-report.pdf).
- WHOQOL Group. 1994. "Development of the WHOQOL: Rationale and Current Status." *International Journal of Mental Health* 23 (3): 24–56.
- Wolpe, Joseph, and Peter J. Lang. 1964. "Fear Survey Schedule III." *PsycTESTS Dataset*. <https://doi.org/10.1037/t13760-000>.
- World Health Organisation. 2017. "Depression and Other Common Mental Disorders: Global Health Estimates." <http://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf;jsessionid=30EE4D2178D63E3F6CD72073F6526614?sequence=1>.